Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer

Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer

Endometrial cancer is the most commonly diagnosed gynaecological malignancy. Unfortunately, 15–20% of women demonstrate persistent or recurrent tumours that are refractory to current chemotherapies. We previously identified activating mutations in fibroblast growth factor receptor 2 (FGFR2) in 12% (...

Full description

Bibliographic Details
Main Authors: Leisl M. Packer, Samantha J. Stehbens, Vanessa F. Bonazzi, Jennifer H. Gunter, Robert J. Ju, Micheal Ward, Michael G. Gartside, Sara A. Byron, Pamela M. Pollock
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Molecular Oncology
Subjects:
ABT263
BGJ398
cell death
endometrial cancer
FGFR2 inhibitor
Online Access:https://doi.org/10.1002/1878-0261.12422

Similar Items

Similar Items